Ananthan Sadagopan

Ananthan Sadagopan

Auto-generated profile, based on publicly available information

Ananthan Sadagopan

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
FKFilippos Kontos
Filippos Kontos
TMTheodoros Michelakos
Theodoros Michelakos
TKTomohiro Kurokawa
Tomohiro Kurokawa
ASAnanthan Sadagopan
Ananthan Sadagopan
JSJoseph H. Schwab
Joseph H. Schwab
Soldano FerroneSoldano Ferrone
Soldano Ferrone
The recent impressive clinical responses to antibody-based immunotherapy have prompted the identification of clinically relevant tumor antigens that can serve as targets in solid tumors. Among them, B7-H3, a member of the B7 ligand family, represents an attractive target for antibody-based immunotherapy, it is overexpressed on differentiated malignant cells and cancer-initiating cells, with limited heterogeneity, and high frequency (60% of 25,000 tumor samples) in many different cancer types, but has a limited expression at low level in normal tissues. In nonmalignant tissues, B7-H3 has a predominantly inhibitory role in adaptive immunity, suppressing T-cell activation and proliferation. In malignant tissues, B7-H3 inhibits tumor antigen–specific immune responses, leading to a protumorigenic effect. B7-H3 also has nonimmunologic protumorigenic functions, such as promoting migration and invasion, angiogenesis, chemoresistance, and endothelial-to-mesenchymal transition, as well as affecting tumor cell metabolism. As a result, B7-H3 expression in tumors is associated with poor prognosis. Although experimental B7-H3 silencing reduces cancer cell malignant potential, there has been limited emphasis on the development of B7-H3–blocking antibodies, most likely because the B7-H3 receptor remains unknown. Instead, many antibody-based strategies utilizing distinct effector mechanisms to target B7-H3–expressing cancer cells have been developed. These strategies have demonstrated potent antitumor activity and acceptable safety profiles in preclinical models. Ongoing clinical trials are assessing their safety and efficacy in patients. Identification of the B7-H3 receptor will improve our understanding of its role in tumor immunity, and will suggest rational strategies to develop blocking antibodies, which may enhance the therapeutic efficacy of tumor immunity.

4 January 2022 in Cell Reports
Verified
Journal Article
Open access
ZBZiad Bakouny
Ziad Bakouny
ASAnanthan Sadagopan
Ananthan Sadagopan
PRPraful Ravi
Praful Ravi
NMNebiyou Y. Metaferia
Nebiyou Y. Metaferia
JLJiao Li
Jiao Li
SVSrinivas R. Viswanathan
Srinivas R. Viswanathan
Translocation renal cell carcinoma (tRCC) is a poorly-characterized subtype of kidney cancer driven by MiT/TFE gene fusions. Here, we define the landmarks of tRCC through an integrative analysis of 152 patients with tRCC identified across genomic, clinical trial, and retrospective cohorts. Most tRCCs harbor few somatic alterations apart from MiT/TFE fusions and homozygous deletions at chromosome 9p21.3 (19.2% of cases). Transcriptionally, tRCCs display a heightened NRF2-driven antioxidant response that is associated with resistance to targeted therapies. Consistently, we find that outcomes for patients with tRCC treated with vascular endothelial growth factor receptor inhibitors (VEGFR-TKI) are worse than those treated with immune checkpoint inhibition (ICI). Using multiparametric immunofluorescence, we find that the tumors are infiltrated with CD8+ T cells, though the T cells harbor an exhaustion immunophenotype distinct from that of clear cell RCC. Our findings comprehensively define the clinical and molecular features of tRCC and may inspire new therapeutic hypotheses.

18 December 2023 in Nature Chemistry
Verified
Journal Article
Closed access
PDF file
TNTuan M. Nguyen
Tuan M. Nguyen
VSVedagopuram Sreekanth
Vedagopuram Sreekanth
ADArghya Deb
Arghya Deb
PKPraveen Kokkonda
Praveen Kokkonda
PTPraveen K. Tiwari
Praveen K. Tiwari
ACAmit Choudhary
Amit Choudhary

1 March 2021 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
YZYida Zhang
Yida Zhang
LHLile He
Lile He
ASAnanthan Sadagopan
Ananthan Sadagopan
TMTao Ma
Tao Ma
GDGianpietro Dotti
Gianpietro Dotti
XWXinhui Wang
Xinhui Wang
Radiotherapy (RT) is a key treatment for prostate cancer. However, RT resistance can contribute to treatment failure. Prostate cancer stem cells (PCSCs) are radioresistant. We recently found that fractionated irradiation (FIR) upregulates expression of the immune checkpoint B7-H3 (CD276) on PCSCs and bulk cells in each prostate cancer cell line tested. These findings prompted us to investigate whether B7-H3 targeting chimeric antigen receptor (CAR) T cells, which may abrogate function of an immune checkpoint and mediate lysis of targeted cells, can target RT-resistant PCSCs in vitro and in vivo. B7-H3 expression is naturally higher on PCSCs than bulk prostate cancer cells and cytotoxicity of B7-H3 CAR T cells to PCSCs is more potent than to bulk prostate cancer cells. Furthermore, FIR significantly upregulates B7-H3 expression on PCSCs and bulk prostate cancer cells. The duration of FIR or single-dose irradiation-induced further upregulation of B7-H3 on bulk prostate cancer cells and PCSCs lasts for up to 3 days. B7-H3 CAR T-cell cytotoxicity against FIR-resistant PCSCs at a low effector to target ratio of 1:1 was assessed by flow cytometry and sphere formation assays. Further upregulation of B7-H3 expression by FIR made PCSCs even more sensitive to B7-H3 CAR T-cell–mediated killing. Consequently, the FIR and B7-H3 CAR T-cell therapy combination is much more effective than FIR or CAR T cells alone in growth inhibition of hormone-insensitive prostate cancer xenografts in immunodeficient mice. Our work provides a sound basis for further development of this unique combinatorial model of RT and B7-H3 CAR T-cell therapy for prostate cancer. Significance: We demonstrate that FIR significantly upregulates B7-H3 expression by RT-resistant PCSCs and bulk cells; cytotoxicity of B7-H3 CAR T cells to FIR-treated PCSCs is potent and results in significantly improved antitumor efficacy in mice.

9 November 2022 in Cell Systems
Verified
Journal Article
Closed access
ASAnanthan Sadagopan
Ananthan Sadagopan
INImran T. Nasim
Imran T. Nasim
JLJiao Li
Jiao Li
MAMingkee Achom
Mingkee Achom
CZCheng-Zhong Zhang
Cheng-Zhong Zhang
SVSrinivas R. Viswanathan
Srinivas R. Viswanathan

1 January 2019
Verified
Journal Article
Closed access
XZXiao Zhang
Xiao Zhang
PHPan Hu
Pan Hu
SDShi-Ying Ding
Shi-Ying Ding
TSTing Sun
Ting Sun
LLLing Liu
Ling Liu
XWXinhui Wang
Xinhui Wang